Business
MoleMate "Optical Biopsy" Poised to Improve The Quality of Care for Patients with Moles
MedX Survey Confirms Almost 90% of Moles Biopsied Are Benign MISSISSAUGA, ON, May 16,...
About this update from Medx Health Corp.
[{"type":"text","content":"\n\n\n\n\n\nMedX Survey Confirms Almost 90% of Moles Biopsied Are Benign\n\n\nMISSISSAUGA, ON, May 16, 2012 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy\n and light imaging systems, announced the results of a recent MedX\n survey launched via a press release on April 12, 2012 and concluded in\n May, which has been designated as Melanoma/Skin Cancer Prevention Month\n by the American Academy of Dermatology.  The results over the last\n month confirm earlier studies that show that most moles (90%) that are\n biopsied are benign and did not need to be removed.\n\n\nAlternative approaches are therefore required to increase the precision\n of assessment of pigmented skin lesions. MoleMate uses light waves to\n create images that allow physicians to see below the mole, under the\n skin, and determine if a mole is malignant, within seconds, without\n surgery, resulting in a sharp reduction of the moles removed, or\n biopsied.  MoleMate allows an \"optical biopsy\" and reduces the pain and\n stress for patients and reduces the cost of care to the medical system.\n\n\nMedX says that with 14 million Americans living with a history of\n melanoma and non-melanoma skin cancer, this technology is designed with\n the welfare of patients in mind, and that according to the Canadian and\n US Cancer Societies, when melanoma is detected early, the survival rate\n is about 99 per cent.\n\n\n\"MoleMate allows physicians and patients to know immediately what a time\n consuming and painful biopsy would have revealed,\" said Steve Guillen,\n President & CEO, and \"fewer surgical biopsies save the health care\n system money, and improve the quality of care of patients with\n suspicious moles.\"\n\n\nAbout MoleMate Imaging and Skin Cancer\n\n\nMoleMate recently received approval from Health Canada, and is\n immediately available and in stock for all Canadian physicians, joining\n their colleagues in Europe, the UK, Australia, and the US, who have\n been utilizing this new pain-free, non-invasive imaging system to 'See\n More', approximately 2mm below the surface of suspicious moles, and\n provide additional information and images related to every mole and all\n types of melanomas and non-melanomas.\n\n\nMoleMate uses a patented device and technology that features a hand-held\n...